Prudent AI Upfront Income calculates qualified income across all loan types with same-day certainty DOVER, Del.–(BUSINESS WIRE)–Prudent AI today launched PrudentPrudent AI Upfront Income calculates qualified income across all loan types with same-day certainty DOVER, Del.–(BUSINESS WIRE)–Prudent AI today launched Prudent

Prudent AI Introduces Industry’s First Universal Income Platform

2026/01/22 01:00
3 min read

Prudent AI Upfront Income calculates qualified income across all loan types with same-day certainty

DOVER, Del.–(BUSINESS WIRE)–Prudent AI today launched Prudent AI Upfront Income, the industry’s first universal income platform designed to calculate qualified income for any loan type in a single tool with same-day certainty.

Using this tool, lenders can upload any income document— W-2s, 1099s, tax returns, bank statements, paystubs—and receive qualifying income calculations instantly. Prudent AI Upfront Income is gamechanging because it means lenders no longer have to switch tools, reconcile results across platforms, or discover income surprises weeks into the process. With faster upfront approval, borrowers get aligned to optimal loan programs immediately based on actual qualifying income.

Previously, mortgage lenders had to juggle multiple income calculation tools, each operating at different speeds with different accuracy standards. In some cases, this meant that it took until Day 28 after initial engagement to uncover a disqualifying factor.

Now, with Prudent AI Upfront Income, Day 28 surprises are replaced with Day One certainty. Using this tool, lenders will know which loan products fit each borrower at intake, not at closing.

“One tool. All income types. All loan programs,” said Jayendran GS, Co-Founder of Prudent AI. “Income silos just became history. Lenders get certainty at intake instead of surprises at closing. That’s the difference between converting leads and losing them. We’re not improving income calculation. We’re eliminating the operational chaos that’s plagued lending for decades.”

For agency loans, Prudent AI Upfront Income automatically extracts data and populates calculator fields for seamless DU submission. For non-QM loans, the platform calculates income according to investor-specific guidelines with identical speed and accuracy. Same workflow. Same velocity. Universal coverage.

Prudent AI Upfront Income delivers same-day qualified income regardless of loan complexity. The platform maintains 100% consistency across all loan types with zero reconciliation between tools. App-hopping, duplicate data entry, and workflow friction that kills conversion rates—all eliminated. Lenders can serve the full spectrum of borrowers with a single workflow that delivers consistent velocity and accuracy.

This represents a fundamental shift in lending economics. The choice between speed and thoroughness no longer exists. Neither do the operational constraints that forced lenders to turn away complex borrowers. Prudent AI Upfront Income makes every income scenario equally accessible, equally fast, equally accurate.

About Prudent AI

Prudent AI provides income certainty and instant prequalification tailored for all mortgage lender types with AI copilots and human intervention. Trusted by the majority of enterprise clients, the company’s comprehensive lending solutions enable lenders to process more loans, reduce operational overhead, and confidently serve previously underserved borrower segments.

For more information, visit www.prudent.ai.

Contacts

Press Contact
Jacob Gaffney

jacob@gaffneyaustin.com
817.471.7627

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26